TKIs (EGFR VEGF BTK etc.)

Delve into the world of TKIs (EGFR VEGF BTK etc.) in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on TKIs (EGFR VEGF BTK etc.) to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Deals

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Group and the China Association Against Epilepsy (CAAE) officially signed a strategic collaboration agreement, committing to a five‑year partnership spanning discipline development, talent cultivation and public welfare assistance.…

October 19, 2026

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

October 19, 2026

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

October 19, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Drug

TKIs (EGFR VEGF BTK etc.)

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

Empowering Chinese Pharma’s Global Expansion

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Allist Pharmaceuticals Secures Breakthrough Therapy Designation for Furmonertinib in EGFR PACC‑Mutated NSCLC

Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones

TransThera Tinengotinib Cholangiocarcinoma Priority Review China

About Company